CompletedPhase 1

A Drug Interaction Study of Albiglutide and Digoxin

An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects

Lead sponsor

GlaxoSmithKline

Asset

Albiglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers

Eligibility highlights

•BMI ≤30•Healthy volunteers

Primary endpoint

•Pharmacokinetic parameters of digoxin with and without albiglutide

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01147718

Org study ID111680

Timeline

Milestones

Study start2010-06-11actual

Study first posted2010-06-22estimated

Primary completion2010-11-29actual

Study completion2010-11-29actual

Last update posted2017-06-12actual

Assets

Investigational agents

Albiglutide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•healthy volunteers

•female subjects must be of nonchildbearing potential

•no clinically significant diseases or clinically significant abnormal laboratory values

•body mass index (BMI) is >/=18 kg and ≤30 kg/m2

•a nonsmoker

Exclusion criteria

•positive test results for hepatitis B, hepatitis C or human immunodeficiency virus

•female subject is pregnant or breast-feeding

•history of any anaphylactic reaction to any drug

•history of significant cardiovascular or pulmonary dysfunction

•current or chronic history of liver disease

•history of alcohol or substance abuse

•history of thyroid disease or dysfunction

•history of gastrointestinal surgery or disease

•history of pancreatitis

•history of cholecystitis or other gallbladder disease

•previously received any GLP-1 mimetic compound (e.g., exenatide)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

The pharmacokinetic parameters of digoxin with and without albiglutide

Time frame:38 days

descriptive

Secondary/protocol endpoint

Safety of digoxin with and without albiglutide

Time frame:38 days

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
Postgraduate medicine2014 Nov (month)PMID25387217doi:10.3810/pgm.2014.11.2836via clinicaltrials gov reference derived + pubmed nct search
Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Postgraduate medicine2012 Nov (month)PMID23322139doi:10.3810/pgm.2012.11.2613via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.